Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.65, demonstrating a -4.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.26%.

Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. For its second quarter, Recursion earned $19.2 million in ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.03, moving -6.85% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.52%.

Most researchers are surrounded by notes, on paper, in folders, and scattered across apps. And yet, many still feel like they can’t make real sense of what they know. If that sounds familiar, you’re ...

The latest trading session saw Recursion Pharmaceuticals (RXRX) ending at $7.25, denoting a +0.14% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.76 ...

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...